Pivotal trial data for EP0031 in RET +ve advanced NSCLC, to be presented at ASCO 2026 London, May 22, 2026 Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive [...]
EP0031 ELCC Pre-Clinical Poster 25th March 2026 Download as PDF About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise [...]
EP0031 Poster British Thoracic Oncology Group Download as PDF About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the [...]
